These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. Tang KM; Jang EK; Haslam RJ Eur J Pharmacol; 1994 Jun; 268(1):105-14. PubMed ID: 7925608 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481 [TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089 [TBL] [Abstract][Full Text] [Related]
11. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro. Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383 [TBL] [Abstract][Full Text] [Related]
12. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473 [TBL] [Abstract][Full Text] [Related]
13. 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. Martinez GR; Walker KA; Hirschfeld DR; Bruno JJ; Yang DS; Maloney PJ J Med Chem; 1992 Feb; 35(4):620-8. PubMed ID: 1311763 [TBL] [Abstract][Full Text] [Related]
14. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets. Lam SC; Guccione MA; Packham MA; Mustard JF Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543 [TBL] [Abstract][Full Text] [Related]
15. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Marcoz P; Prigent AF; Lagarde M; Nemoz G Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905 [TBL] [Abstract][Full Text] [Related]
17. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. Meanwell NA; Roth HR; Smith EC; Wedding DL; Wright JJ; Fleming JS; Gillespie E J Med Chem; 1991 Sep; 34(9):2906-16. PubMed ID: 1654430 [TBL] [Abstract][Full Text] [Related]
18. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets. Simpson AW; Reeves ML; Rink TJ Biochem Pharmacol; 1988 Jun; 37(12):2315-20. PubMed ID: 2455518 [TBL] [Abstract][Full Text] [Related]
19. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro. Ruppert D; Weithmann KU Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426 [TBL] [Abstract][Full Text] [Related]
20. Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities. Lugnier C; Gauthier C; Le Bec A; Soustre H Am J Physiol; 1992 Mar; 262(3 Pt 2):H654-60. PubMed ID: 1373036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]